Abstract
Randomized clinical trials have demonstrated that the implantable cardioverter defibrillator (ICD) reduces mortality in heart failure patients with reduced systolic function but have excluded patients with advanced chronic kidney disease (CKD). We investigated the impact of ICDs on survival in patients with moderate-to-severe CKD, including those requiring dialysis therapy (DT). Patients followed at our institution between 1998 and 2008 with left ventricular ejection fraction (LVEF) ≤35% and CKD, defined as glomerular filtration rate (GFR) <60 mL/min, or who were on DT were identified from the medical record. The primary endpoint of all-cause death was analyzed by ICD status. A total of 78 patients (\( {\hbox{age}} = 66\pm 12\;{\hbox{years}} \), 73% men, \( {\hbox{EF}} = 0.24\pm 0.07 \), GFR 39 ± 12 mL/min in those not on DT) of whom 32 had an ICD were followed for 2.7 ± 2.3 years. In the DT (n = 45) cohort, the presence of an ICD did not impact survival. In the CKD with no DT cohort (n = 33), survival was significantly better in patients with an ICD (2-year survival 80% vs. 54%, p = 0.027), and this benefit persisted after adjusting for gender, race, GFR, digoxin use, and presence of coronary disease, heart failure, or hypertension in a multivariate Cox regression model (odd ratio = 0.23, adjusted p = 0.028). Defibrillators improve survival in CKD patients with LVEF ≤ 35%, whereas patients requiring DT do not appear to extract such benefit. Further studies with larger number of patients are required to confirm these findings.
Similar content being viewed by others
References
Coresh, J., Astor, B. C., Greene, T., Eknoyan, G., & Levey, A. S. (2003). Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. American Journal of Kidney Diseases, 41, 1–12.
National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. (2006). US Renal Data System UADRAoE-SRDitUS. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases.
Herzog, C. A. (2007). Can we prevent sudden cardiac death in dialysis patients? Clinical Journal of the American Society of Nephrology, 2, 410–412.
Bardy, G. H., Lee, K. L., Mark, D. B., Poole, J. E., Packer, D. L., Boineau, R., et al. (2005). Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. New England Journal of Medicine, 352, 225–237.
Moss, A. J., Hall, W. J., Cannom, D. S., Daubert, J. P., Higgins, S. L., Klein, H., et al. (1996). Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. New England Journal of Medicine, 335, 1933–1940.
Moss, A. J., Zareba, W., Hall, W. J., Klein, H., Wilber, D. J., Cannom, D. S., et al. (2002). Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. New England Journal of Medicine, 346, 877–883.
Epstein, A. E., DiMarco, J. P., Ellenbogen, K. A., Estes, N. A., 3rd, Freedman, R. A., Gettes, L. S., et al. (2008). ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 117(21), e350–e408. Writing Committee to Revise the ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons.
Mark, P. B., Johnston, N., Groenning, B. A., Foster, J. E., Blyth, K. G., Martin, T. N., et al. (2006). Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging. Kidney International, 69, 1839–1845.
Chen-Scarabelli, C., & Scarabelli, T. M. (2007). Chronic renal insufficiency is an independent predictor of mortality in implantable cardioverter-defibrillator recipients. Pacing and Clinical Electrophysiology, 30, 371–376.
Chonchol, M., Goldenberg, I., Moss, A. J., McNitt, S., & Cheung, A. K. (2007). Risk factors for sudden cardiac death in patients with chronic renal insufficiency and left ventricular dysfunction. American Journal of Nephrology, 27, 7–14.
Ito, I., Kono, K., Shinbo, G., Tadokoro, K., Abe, C., Takemura, N., et al. (2009). Implantable cardioverter defibrillator in maintenance hemodialysis patients with ventricular tachyarrhythmias: a single-center experience. Hemodialysis International, 13, 48–54.
Robin, J., Weinberg, K., Tiongson, J., Carnethon, M., Reddy, M., Ciaccio, C., et al. (2006). Renal dialysis as a risk factor for appropriate therapies and mortality in implantable cardioverter-defibrillator recipients. Heart Rhythm, 3, 1196–1201.
Wase, A., Basit, A., Nazir, R., Jamal, A., Shah, S., Khan, T., et al. (2004). Impact of chronic kidney disease upon survival among implantable cardioverter-defibrillator recipients. Journal of Interventional CardiacElectrophysiology, 11, 199–204.
Hreybe, H., Ezzeddine, R., Bedi, M., Barrington, W., Bazaz, R., Ganz, L. I., et al. (2006). Renal insufficiency predicts the time to first appropriate defibrillator shock. American Heart Journal, 151, 852–856.
Grothe, C., Belasco, A., Bettencourt, A., Diccini, S., Vianna, L., Pignatari, A., et al. (2009). Lethality of endocarditis due to S. aureus among patients on hemodialysis. Nephrology Nursing Journal, 36, 613–619.
Thomson, P., Stirling, C., Traynor, J., Morris, S., Mactier, R. (2010). A prospective observational study of catheter-related bacteraemia and thrombosis in a haemodialysis cohort: Univariate and multivariate analyses of risk association. Nephrology, Dialysis, Transplantation. doi:10.1093/ndt/gfp667.
Cuculich, P. S., Sanchez, J. M., Kerzner, R., Greenberg, S. L., Sengupta, J., Chen, J., et al. (2007). Poor prognosis for patients with chronic kidney disease despite ICD therapy for the primary prevention of sudden death. Pacing and Clinical Electrophysiology, 30, 207–213.
Hreybe, H., Razak, E., & Saba, S. (2007). Effect of end-stage renal failure and hemodialysis on mortality rates in implantable cardioverter-defibrillator recipients. Pacing and Clinical Electrophysiology, 30, 1091–1095.
Herzog, C. A., Li, S., Weinhandl, E. D., Strief, J. W., Collins, A. J., & Gilbertson, D. T. (2005). Survival of dialysis patients after cardiac arrest and the impact of implantable cardioverter defibrillators. Kidney International, 68, 818–825.
de Bie, M. K., Lekkerkerker, J. C., van Dam, B., Gaasbeek, A., van Buren, M., Putter, H., et al. (2008). Prevention of sudden cardiac death: rationale and design of the Implantable Cardioverter Defibrillators in Dialysis patients (ICD2) Trial–a prospective pilot study. Current Medical Research and Opinion, 24, 2151–2157.
Disclosures
None
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Khan, F., Adelstein, E. & Saba, S. Implantable cardioverter defibrillators confer survival benefit in patients with renal insufficiency but not in dialysis-dependent patients. J Interv Card Electrophysiol 28, 117–123 (2010). https://doi.org/10.1007/s10840-010-9484-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10840-010-9484-6